There are two platforms housed at the Stem Cell Institute which support local and national activity in the biomedical application of pluripotent stem cells:
- NIHR Cambridge Biomedical Centre (BRC) hIPSCs core facility
- UK RMP Pluripotent Stem Cell Platform (PSCP).
NIHR/BRC hIPSC Core Facility
The NIHR Cambridge Biomedical Centre (BRC) hIPSCs core facility was created in 2009 to promote the clinical applications of human Induced Pluripotent Stem Cells (hIPSCs). The main activity of this platform is the production of hIPSC lines on demand for the development of in vitro models of disease, compatible with drug development and basic mechanistic studies. In addition, genome editing of hIPSCs for gene correction or for gene mutation is a growing activity for the BRC hIPSCs core facility. This platform also provides training to derive, grow and characterise hIPSC lines. Finally, the BRC hIPSC core facility is managing several research and development programs aiming to establish new methods of differentiation, inducible systems for gene targeting and more recently derivation of organoid from a diversity of organs including gut and liver.
During the past seven years, the BRC hIPSCs core facility has derived and characterised hIPSCs lines from 600 patients suffering from neurodegenerative diseases, cardiovascular syndromes, metabolic and blood disorders. These projects have been directed by clinicians and basic scientists associated with different institutions in Europe and also with diverse BRC themes related to Neurosciences, Metabolic Science, Cardiovascular Medicine, Haematology, Surgery and Hepatology/Thoracic Medicine.
Located in the Anne McLaren Laboratory, the BRC hIPSC core facility benefits from state of the art environment for stem cell research and also from the broad expertise of research groups of the Stem Cell Institute.
- Ludovic Vallier - Director
- An-Sofie Lenaerts – Manager
- Sophie Glen – Research Assistant
- June Kadiwala – Research Assistant
- Paulina Materek – Research Assistant
- Kirsten Snijders – Research Assistant
UK RMP Pluripotent Stem Cell Platform (PSCP)
The UK RMP’s Cell Behaviour, Differentiation and Manufacturing Hub, the Pluripotent Stem Cell Platform (PSCP), builds upon emerging pluripotent stem cell (PSC) technologies to establish optimised processes for consistent and scalable cell manufacturing to meet the requirements of clinicians, regulatory authorities and industry for cell therapy applications. The PSCP commenced in February 2014.
The PSCP is developing protocols for transgene-free, EUCTD-compliant, production, expansion and safety qualification of PSCs; methods to understand and minimise functionally significant genetic or epigenetic variants during PSC manufacturing; standardised PSC differentiation protocols to underpin the derivation, manufacture and banking of therapeutically relevant, lineage-specific, intermediate stem cells.
The PSCP will also provide qualified processes for manufacturing regulatory compliant PSC products suitable for clinical use. As disease exemplars the PSCP will focus initially on the degenerative conditions of Parkinson's disease and neuropathic deafness.